Cafedrine

DB12926

small molecule investigational

Deskripsi

Cafedrine is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

Struktur Molekul 2D

Berat 357.414
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

608 Data
Deferasirox The serum concentration of Cafedrine can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Cafedrine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Cafedrine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Cafedrine can be decreased when it is combined with Teriflunomide.
Regadenoson Cafedrine may decrease effectiveness of Regadenoson as a diagnostic agent.
Adalimumab The serum concentration of Cafedrine can be decreased when it is combined with Adalimumab.
Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Cafedrine.
Allopurinol The serum concentration of Cafedrine can be increased when it is combined with Allopurinol.
Carbamazepine The serum concentration of Cafedrine can be decreased when it is combined with Carbamazepine.
Cimetidine The metabolism of Cafedrine can be decreased when combined with Cimetidine.
Disulfiram The serum concentration of Cafedrine can be increased when it is combined with Disulfiram.
Febuxostat The serum concentration of the active metabolites of Cafedrine can be increased when Cafedrine is used in combination with Febuxostat.
Fluvoxamine The metabolism of Cafedrine can be decreased when combined with Fluvoxamine.
Formoterol The risk or severity of hypokalemia can be increased when Cafedrine is combined with Formoterol.
Indacaterol The risk or severity of adverse effects can be increased when Cafedrine is combined with Indacaterol.
Isoniazid The serum concentration of Cafedrine can be increased when it is combined with Isoniazid.
Lithium citrate The serum concentration of Lithium citrate can be decreased when it is combined with Cafedrine.
Lithium carbonate The serum concentration of Lithium carbonate can be decreased when it is combined with Cafedrine.
Lithium hydroxide The serum concentration of Lithium hydroxide can be decreased when it is combined with Cafedrine.
Mexiletine The metabolism of Cafedrine can be decreased when combined with Mexiletine.
Olodaterol Cafedrine may increase the hyperkalemic activities of Olodaterol.
Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with Cafedrine.
Pentoxifylline The serum concentration of Cafedrine can be increased when it is combined with Pentoxifylline.
Phenytoin The serum concentration of Cafedrine can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of Cafedrine can be decreased when it is combined with Fosphenytoin.
Propafenone The serum concentration of Cafedrine can be increased when it is combined with Propafenone.
Quinine The serum concentration of Cafedrine can be increased when it is combined with Quinine.
Quinidine The serum concentration of Cafedrine can be increased when it is combined with Quinidine.
Riociguat Cafedrine may increase the hypotensive activities of Riociguat.
Thiabendazole The metabolism of Cafedrine can be decreased when combined with Thiabendazole.
Ticlopidine The metabolism of Cafedrine can be decreased when combined with Ticlopidine.
Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Cafedrine.
Probenecid The serum concentration of Cafedrine can be increased when it is combined with Probenecid.
Abiraterone The serum concentration of Cafedrine can be increased when it is combined with Abiraterone.
Isoprenaline The serum concentration of Cafedrine can be decreased when it is combined with Isoprenaline.
Cyproterone acetate The metabolism of Cafedrine can be increased when combined with Cyproterone acetate.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Cafedrine.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Cafedrine.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Cafedrine.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Cafedrine.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Cafedrine.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Cafedrine.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Cafedrine.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Cafedrine.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Cafedrine.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Cafedrine.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Cafedrine.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Cafedrine.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Cafedrine.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Cafedrine.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Cafedrine.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Cafedrine.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Cafedrine.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Cafedrine.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Cafedrine.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Cafedrine.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Cafedrine.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Cafedrine.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Cafedrine.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Cafedrine.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Cafedrine.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Cafedrine.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Cafedrine.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Cafedrine.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Cafedrine.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Cafedrine.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Cafedrine.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Cafedrine.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Cafedrine.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Cafedrine.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Cafedrine.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Cafedrine.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Cafedrine.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Cafedrine.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Cafedrine.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Cafedrine.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Cafedrine.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Cafedrine.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Cafedrine.
Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Cafedrine.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Cafedrine.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Cafedrine.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Cafedrine.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Cafedrine.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Cafedrine.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Cafedrine.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Cafedrine.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Cafedrine.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Cafedrine.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Cafedrine.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Cafedrine.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Cafedrine.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Cafedrine.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Cafedrine.
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Cafedrine.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Cafedrine.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Cafedrine.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Cafedrine.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Cafedrine.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Cafedrine.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul